|
Study
|
Objective
|
Contact
|
|
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects with Chemorefractory Metastatic Colorectal Cancer
|
This research is being done to find out if an investigational drug (antibody) called MORAb-004 is safe, well-tolerated, effective in the treatment of metastatic colorectal cancer, how it is used by the body, how your genetics and the study drug work together, and how it impacts your quality of life.
|
Principal Investigator(s):
Keith E. Stuart, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Kathleen (Kai) Sherman.
|
|
CALGB/SWOG C80702: A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer
|
This study is being done to evaluate the effects (good and bad) of different chemotherapy treatments. One of the common combinations of chemotherapy drugs used to treat your type of cancer includes 5-fluorouracil (also called 5-FU), leucovorin and oxaliplatin, and is also called “FOLFOX”. At the present time, the Food and Drug Administration (FDA) has approved each of these drugs as treatment for colon cancer. FOLFOX is a standard treatment used to prevent colon cancer from coming back (recurrence).
|
Principal Investigator(s):
Keith E. Stuart, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Kathleen (Kai) Sherman.
|
|
Molecular Analysis of Cancer
|
The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA).
Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer.
|
Principal Investigator(s):
Kimberly R. Christ, PhD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Doreen L. Browne, ,CCRP,
Jane S. Nalwalk,
Linda M. Topjian.
|
|
NSABP P-5: Statin Polyp Prevention Trial In Patients With Resected Colon Cancer
|
This study will look at the effects, good and/or bad, of the drug rosuvastatin (also called Crestor®). Rosuvastatin is a type of drug called a statin. The main purpose of this study is to find out whether or not rosuvastatin is able to prevent colon polyps and CRC from occurring in patients who have already had a colon cancer removed by surgery.
|
Principal Investigator(s):
Keith E. Stuart, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Kathleen (Kai) Sherman.
|